Endogenex

Bringing New Energy to the Treatment of Type 2 Diabetes

Clinical study participant with Type 2 Diabetes shares his story

As the first ReCETTM clinical study site in the United States, Cuyuna Regional Medical Center has seen study participant’s A1C levels decline which has been encouraging for patients and providers.

“Being involved in the study from the beginning, involved in this very exciting study is very rewarding,” said Dr. McCollister, CRMC. “For the patients in the study to date, there have been lots of positives,” Dr. McCollister stated. “The ReCET Procedure’s preliminary results are as expected; everyone has done well, feels well, and we have had no adverse effects.”

The procedure

ReCET is an outpatient procedure whereby a doctor uses a small flexible endoscope under anesthesia to introduce a special catheter through the mouth and past the stomach to the duodenum, the first part of the small intestine. Precise, controlled, electric currents are then applied to the lining of the small intestine. This triggers the body’s natural process of cell regeneration, replacing unhealthy signaling cells with new cells that help the body better manage blood sugar.

Patient sees results

Chad Visser, a 51-year-old police officer from Ironton, Minn., is a patient in the T2D clinical study called REGENT-1. Chad was diagnosed with Type 2 Diabetes in 2017. After educating himself on eating better, hoping to get better control of his diabetes, he was still not satisfied with the results. Even after trying different medications, his A1C numbers (and blood pressure) were still high. In an effort to reduce the risk of the next foreseeable step being put on insulin, Chad decided to participate in the REGENT-1 study, he met the study criteria, and received the ReCET Procedure.

Four months after the procedure, Visser has lost 30 pounds, his A1C went down to 5.7 percent, and he was able to stop taking his blood pressure medication.*

Chad is just one of several patients seeing improved results to control their Type 2 Diabetes as part of the REGENT-1 clinical study. Read the full results and overview of the study on the CRMC website.

*Patient experience is  unique and participation in the study does not  guarantee similar outcomes.